−3.28USD
−174.28 MUSD
44.47 M
About Replimune Group, Inc.
Sector
Industry
CEO
Sushil Patel
Website
Headquarters
Woburn
Employees (FY)
284
Founded
2015
ISIN
US76029N1063
FIGI
BBG00L8Z22R1
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of REPL is 7.12 USD — it has decreased by 0.28% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Replimune Group, Inc. stocks are traded under the ticker REPL.
Replimune Group, Inc. is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Replimune Group, Inc. has a max estimate of 19.00 USD and a min estimate of 10.00 USD.
REPL earnings for the last quarter are −0.90 USD whereas the estimation was −0.81 USD which accounts for −10.64% surprise. Estimated earnings for the next quarter are −0.89 USD. See more details about Replimune Group, Inc. earnings.
Yes, you can track Replimune Group, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, REPL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Replimune Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 284.00 employees. See our rating of the largest employees — is Replimune Group, Inc. on this list?